Products of Shire PLC's new addition Baxalta lead the hemophilia market with around a 50% market share in value terms – and the enlarged Dublin-based group says it aims to preserve that leadership with innovative drugs "in pursuit of a bleed-free world."
Shire's hemophilia portfolio – acquired with its $32bn acquisition of Baxalta Inc. in June – comprises a broad portfolio...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?